Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroneticsSTIM -0.84%57 10-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates STIM with a GF Score™ of 57/100 and a GF Value™ of $1.78 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 451 Medical Devices & Instruments companies, Neuronetics ranks worse than 221729.27% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Neuronetics's current 10-Year Share Buyback Ratio was 0.00%.
STIM's 10-Year Share Buyback Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -3.3 * Ranked among companies with meaningful 10-Year Share Buyback Ratio only.
Neuronetics (NAS:STIM) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Neuronetics 10-Year Share Buyback Ratio Related Terms
STIM vs MXCT, CVRX, RCEL: 10-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Neuronetics's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuronetics 10-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neuronetics's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Neuronetics's 10-Year Share Buyback Ratio falls into.
Neuronetics 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of 0.00 mean?
Neuronetics (STIM) has a 10-Year Share Buyback Ratio of 0.00 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Neuronetics and its competitors. According to the industry distribution chart, Neuronetics ranks #999999 out of 451 companies in the Medical Devices & Instruments industry.
Is Neuronetics' 10-Year Share Buyback Ratio too high?
Neuronetics' current 10-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Neuronetics ranks #999999 out of 451 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Neuronetics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuronetics' 10-Year Share Buyback Ratio compare to MXCT and CVRX?
According to the Medical Devices & Instruments industry distribution chart, Neuronetics ranks #999999 out of 451 companies for 10-Year Share Buyback Ratio. This places Neuronetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 10-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Neuronetics and its competitors. Neuronetics's current 10-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuronetics stock overvalued right now?
Based on GuruFocus' analysis, Neuronetics (STIM) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.78, compared to a current price of $2.97 — trading 66.9% above its estimated fair value. The current 10-Year Share Buyback Ratio is 0.00. Neuronetics' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Neuronetics (STIM), the current 10-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuronetics (STIM) Overvalued in 2026?
Based on GuruFocus' analysis, Neuronetics stock appears to be overvalued.
The current stock price of $2.97 is trading 66.9% above its estimated GF Value™ of $1.78.
GuruFocus considers Neuronetics to be Significantly Overvalued.
Key valuation signals for STIM:
10-Year Share Buyback Ratio: 0.00
GF Value™: $1.78 vs. price of $2.97 (66.9% above fair value)
No single metric tells the full story. See the STIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
57GF Score
Get the complete analysis for STIM
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STIM has been successfully added to your 
